AKT1 and lymphoma: Decreased SHIP1 expression was found to enhance AKT signaling, subsequently promoting cell proliferation and survival and ultimately leading to lymphoma.485 Cobomarsen, a miR-155 inhibitor, has been evaluated in multiple types of lymphoma (NCT 02580552).